04 December 2017
Europe
Asthma , Allergy
- Healthcare

EFA represented patients at the European Rhinology Research Forum 2017 on 9-10 November 2017, organized by the European Forum for Research and Education in Allergy and Airway diseases (EUFOREA) and the European Rhinologic Society (ERS).

Allergy, upper and lower respiratory diseases, multimorbidity in allergic diseases and precision medicines where some of the subjects discussed at the forum, which was crucial for patients to learn more about the latest development on treatments and cure for allergy and asthma.

EFA was actively participating in three brainstorming sessions. Secretary of Board Carlos contributed at patients-centered guidelines for people with chronic respiratory diseases session. EFA Projects Manager Giuseppe De Carlo moderated the ehealth and mhealth opportunities session, that discussed how to unlock the full potential mobile technology and e-health can bring to the treatment and management of upper airways diseases.

EFA Director of Strategy and Policy Roberta Savli presented in one of the brainstorming sessions where she explained how endotype driven treatment could be useful for people with respiratory diseases. Roberta pointed out that for severe asthma cases endotype-driven treatments could be explored as a means to better control the disease. Moreover, in the long-term, these treatments could be a success if aimed at help preventing, even cure, the disease.

EFA is delighted of this evolving exchange with the EUFOREA, especially for the non-allergic and chronic rhinitis and we look forward to strengthened collaboration.

Find the full programme

Dear Visitor,

for regularly updated information on Covid-19 for allergy and respiratory patients, please consult our Covid-19 resource and information hub.
Stay safe!
The EFA Team